News

(Bloomberg) -- OpenAI has appointed two financial services executives to its board of directors, drawing on their experience as the company moves toward a Wall Street debut. Most Read from BloombergApple to Launch ‘Upgrade’ Device Leasing Program With Klarna to Spur SalesChina AI Sensation Moonshot’s Gamble on Big Models Pays OffYemen’s Houthis to Impose Maritime Blockade on Saudi ArabiaTrump Vows 50% Tariff on Canadian Goods Using Depression-Era LawMoonshot’s Kimi K3 May Be More About Memory Th

Broadcom (AVGO) just landed a customer that most investors will never think about when they buy the stock. Broadcom is currently known for one thing: custom AI chips. Yet the deal that could matter most for the next few years has nothing to do with silicon. On July 16, 2026, Broadcom and Standard ...

MSCI's second-quarter earnings were fine, but the stock is selling off after missing analysts' expectations.

Twilio Inc (NYSE:TWLO) is expected to deliver second quarter results that exceed expectations on revenue and operating income, with investors likely to focus on whether the communications software company's gross profit growth can remain in the mid-teens during the second half of the year,...

The defense and aerospace company said Tuesday that it expects $43.75 billion to $44.25 billion in sales in 2026, adding a quarter-billion dollars to its previous targets. Adjusted earnings are now projected at $28.

EPS surged 25% as revenue growth and efficiency gains accelerated across all segments.

Net income surged 45% as revenue hit a decade high of $24.8 billion.

Record revenue and earnings driven by M&A surge and AI infrastructure investment cycle.

Net income surged 27% as investment banking and trading revenue hit record levels.

The World Cup produced the sort of demand shock airlines crave, with international travelers booking late, accepting connections and paying unusually high fares. But that didn’t change the economics of the industry. American Airlines (AAL) added 27,000 seats on 12 routes and offered 1.45 million ...

Another restructuring is rattling nerves days before earnings. The cash flow math, however, tells a calmer story.

Boeing added to its order book at the Farnborough International Airshow with new commitments from airlines and cargo operators.

Alphabet and Tesla Are Due to Report Results Wednesday Afternoon

Tesla stock has underperformed in 2026, and markets are now looking forward to CEO Elon Musk's commentary during the upcoming Q2 earnings call.

Cybersecurity stocks' lofty valuations warrant caution ahead of upcoming quarterly results, especial

MEXICO CITY, July 21 (Reuters) - U. and Mexican trade negotiators launched a third round of bilateral talks on Tuesday to try to revise the North American trade agreement, just as President Donald Trump said he would impose new duties on Canada.

Coinbase Global Inc. CEO Brian Armstrong said on Sunday that Bitcoin’s long-term price performance is primarily a measure of how much people “fear” inflation. ‘Structural’ Problems With Bitcoin Armstrong responded to venture capitalist Chamath Palihapitiya’s take on the “structural” headwinds...

Microsoft earnings are coming up. Aim to profit from the software maker's report by selling an options spread with maximum risk of $415.

SK Hynix recently completed a $26.5 billion secondary listing on the Nasdaq.

ServiceNow Inc (NYSE:NOW, XETRA:4S0) is expected to report a solid second-quarter performance, with Jefferies analysts forecasting results above guidance for key subscription metrics and a potential increase to its full-year subscription revenue outlook, supported by strong execution, early...

Bloom Energy Rockets Higher on AI Data Center Contract, Analyst Support

Sony Music Entertainment on Monday filed a new lawsuit against AI startup Udio, alleging the company infringed on the copyrights of more than 30,000 recordings.

Vicor Corp (VICR) reports a 26.9% sequential revenue increase and outlines plans for a second fab to support future growth.

The U.S. 30-year bond futures continue to consolidate in July 2026. Long-term interest rates remain elevated as the legacy of the global pandemic and geopolitical events has caused stubborn inflationary pressures.

AI spending and cloud growth will drive the reaction

<body><p>STORY: :: Novo Nordisk claims misleading ads in Eli Lilly weight-loss drug lawsuit</p><p>:: July 21, 2026</p><p>:: Maggie Fick, European Pharma Industry Correspondent</p><p>"Novo Nordisk sued rival Eli Lilly in a U.S. federal court on Tuesday, accusing the U.S. drugmaker of false advertising and claiming its weight-loss medicines outperform Novo's drugs." //</p><p>"Novo is alleging in its suit that Lilly's advertisements compare weight-loss results of about 50 pounds for its drug Zepbound with about 33 pounds for Wegovy, even though no head-to-head clinical trial has compared the highest approved doses of the medicines."</p><p>"Pharmaceutical companies regularly sue each other over claims related to patent infringement, for example, but false advertising suits, such as the one filed today, are less common."</p><p>"Novo Nordisk was first to market with its weight-loss injection Wegovy several years ago, but it later lost the lead to Eli Lilly, after that company launched a rival injection called Zepbound in the United States. Last year, Novo replaced its CEO and was forced to issue multiple profit warnings as it fell further behind Eli Lilly in this really competitive and booming obesity drug market, which analysts expect to be worth more than $100 billion by 2030. This year, Novo has actually sort of landed a counterpunch with its oral Wegovy pill. It was able to launch that drug ahead of Eli Lilly. Lilly has, in April, launched its own pill, a weight-loss pill. But Novo has managed to keep up strong sales even since the launch of Lilly's pill."</p><p>"Both companies report quarterly results in the next couple of weeks."</p><p>:: Novo Nordisk</p><p>:: Eli Lilly</p><p>The Danish company filed the lawsuit in U.S. District Court ‌in New Jersey, alleging Lilly violated federal and state false advertising and unfair competition laws, including the Lanham Act, through nationwide advertising campaigns for obesity drug Zepbound and diabetes treatment Mounjaro.</p><p>Novo alleges Lilly compared the highest approved doses of its medicines with lower doses of Novo's Wegovy and Ozempic while omitting newer, higher-dose versions that Novo says deliver greater weight loss.</p><p>But Indianapolis-based Eli Lilly said it stands firmly behind its ads, which are based on the results of its SURMOUNT-5 trial. That ⁠trial — completed in 2024 — compared patients on 10 mg or 15 mg of Lilly's Zepbound to patients on 1.7 mg or 2.4 mg doses of Wegovy. The FDA approved ​a 7.2 mg dose of Wegovy in March of this year.</p></body>

Shares of Coinbase Global jumped Tuesday after a major hurdle facing a key crypto bill was cleared. The White House and a group of senators led by Sen. Cynthia Lummis (R., Wyo.) and Sen. Bernie Moreno (R.

Financial advisors say most public companies underperform for at least a year post-IPO, and investors should ask themselves whether conviction or FOMO is driving their interest.

Highly anticipated GE Vernova earnings for the second quarter early Wednesday will provide the latest insights into AI-driven demand for gas turbines and electrical transformers. GE Vernova confirmed in June that its massive, heavy-duty gas turbines are basically sold out through 2029. Big Tech companies aggressively purchased the gas turbines to power their artificial-intelligence (AI) data-center campuses by themselves, with regionals grids unable to meet massive electricity demand.

Analysts believe the raised revenue outlook is good news for memory chipmakers.